Clinical Research Directory

Inclusion Criteria: * Biopsy proven high-grade glioma (HGG) as defined by 2016 World Health Organization (WHO) Classification Criteria, Grade 3-4 including: * Anaplastic astrocytoma * Anaplastic ganglioglioma * Anaplastic oligodendroglioma. * Anaplastic pleomorphic xanthoastrocytoma, * Glioblastoma OR as defined by the 2021 WHO Classification Criteria as molecularly characterized: * Non-pontine diffuse midline glioma, H3 K27-altered, * Diffuse hemispheric glioma, H3 G34-mutant * Diffuse pediatric HGG, H3/IDH-wildtype * Infant-type hemispheric glioma * High-grade astrocytoma with piloid features * High-grade pleomorphic xanthoastrocytoma * IDH-mutant diffuse glioma with homozygous cyclin- dependent kinase inhibitor 2A/B (CDKN2A/B) deletion, * IDH-mutant and 1p/19q co-deleted oligodendroglioma * IDH-mutant astrocytoma with homozygous CDKN2A/B deletion * Contraceptive use should be consistent with local regulations for participants in clinical studies. * Radiotherapy initiated within 6 weeks (+1 week) of diagnosis and administered over 6 weeks (±1 week). Participants \<3 years of age, considered not suitable for radiotherapy may be eligible. * Minimum of 4 weeks between completion of radiation and Cycle 1 Day 1 (C1D1). * Maximum of 8 weeks between completion of radiation and C1D1. Exceptional circumstances can be discussed with the medical monitor. * Acute effects of prior therapies must be Grade ≤1 unless deemed clinically insignificant by the investigator. * Adequate hematologic and organ function ≤7 days prior to C1D1 * Life expectancy of ≥8 weeks and deemed likely to complete at least 1 cycle of treatment. * A performance score of ≥60 using: 1. Lansky scale for participants \<16 years 2. Karnofsky scale for participants ≥16 years * Able to swallow and/or have a gastric/nasogastric tube. * Any current systemic steroid use dose must be stable or decreasing at least 7 days prior to C1D1. * Able and willing to adhere to study procedures, including frequent blood draws and MRI. * At least 28 days since any major surgery, laparoscopic procedure, or a significant traumatic injury. * Has a body surface area (BSA) of ≥0.2 m2. Exclusion Criteria: Participants are excluded if any of the following apply: * Diffuse Intrinsic Pontine Glioma (DIPG) or diffuse midline glioma located in the pons. * Recurrent or refractory HGG including any recurrence/progression during/after radiotherapy. * Secondary HGG, defined as a previously treated low-grade glioma that now meets high- grade criteria, or that resulted from a previously treated malignancy. * Have known pathogenic somatic mutations appropriate for an anaplastic lymphoma kinase (ALK), B-rapidly accelerated fibrosarcoma (BRAF), or neurotrophic tyrosine receptor kinase (NTRK ) inhibitor, in regions where these therapies are available and deemed appropriate by the investigator. * Prior HGG treatment (including bevacizumab), except for surgery and radiotherapy (with or without concomitant temozolomide). * Current enrollment in another trial deemed incompatible with this study. * Treatment with an investigational product within the last 30 days or 5 half-lives (whichever is longer). * Prior malignancy within the previous 3 years that, per the investigator and the medical monitor, may affect interpretation of study results. * A preexisting medical condition(s) that, per the investigator, would preclude study participation. * Any serious, active, systemic infection requiring IV antibiotic, antifungal, or antiviral therapy, including acute hepatitis B or C, or Human Immunodeficiency Virus at C1D1. * Intolerability or hypersensitivity such as urticaria, anaphylaxis, toxic necrolysis, and/or Stevens-Johnson syndrome to temozolomide, and/or abemaciclib, their excipients, or dacarbazine. * Received a live virus vaccine within 28 days of C1D1. * Pregnant, breastfeeding, or intend to become pregnant during the study.